Emerging Hyperparathyroidism Treatment Market to Witness High Growth

The Hyperparathyroidism Treatment Market is expected to grow at the highest pace owing to the increasing prevalence of hyperparathyroidism and promising drug pipeline. Hyperparathyroidism is a condition in which the parathyroid glands produce excessive parathyroid hormone (PTH), leading to elevated serum calcium levels. Some key advantages of treatments available for hyperparathyroidism include effective management of calcium levels and symptom relief. With rising prevalence of chronic kidney disease and growing geriatric population, the demand for effective therapeutics to manage hyperparathyroidism is increasing rapidly.

 

 

 

Key players operating in the Hyperparathyroidism Treatment Market are Amgen, Teva Pharmaceutical Industries, AbbVie, OSI Pharmaceuticals, Dexcel Pharma.

 

The Hyperparathyroidism Treatment Market increasing prevalence of chronic kidney disease and growing elderly population are the major factors contributing to the rising cases of hyperparathyroidism. As per estimates, over 12% of the global population is expected to be aged 65 years or older by 2030. This rapid rise in the geriatric population makes them more prone to developing hyperparathyroidism. Technological advancements have allowed development of diagnostic tools with high accuracy and precision for detecting mild cases of hyperparathyroidism at an early stage.

 

Growing preference for minimally invasive surgeries - The trend of minimally invasive parathyroidectomies using technology such as gamma probes and rapid PTH assays is growing. These advanced techniques enable focused surgery and reduce recovery time.

 

Personalized treatment approaches - With improved understanding of disease pathology, there is an increased focus on developing personalized treatment regimens. Biomarkers and genetic profiling help determine best therapies for individual patients.

Promising drug pipeline - A number of pharmaceutical companies have drugs in different stages of clinical trials that specifically target hyperparathyroidism. This includes antisense oligonucleotides, calcimimetics, etc.

 

Increasing awareness - With rising disease burden, initiatives are being undertaken to spread awareness among healthcare providers and patients regarding early detection and management of hyperparathyroidism. This will boost diagnostic rates and treatment-seeking behaviour.

 

The COVID-19 pandemic has significantly impacted the Hyperparathyroidism Treatment Market. During the initial phase of lockdowns imposed worldwide, hyperparathyroidism procedures declined sharply as resources were diverted towards COVID care and elective surgeries were postponed. This led to a steep drop in demand for related drugs and therapies. However, as lockdowns eased in late 2020 and 2021, the market has started recovering gradually. Telemedicine emerged as an important tool for ongoing consultations and management of hyperparathyroidism patients during the pandemic. Drug manufacturers also ensured stable supply chains for essential medications.

 

Going forward, as the pandemic situation stabilizes, focus on clearing backlogs of postponed surgeries is expected to drive the market growth. At the same time, risks of virus exposure may continue discouraging elective procedures to some extent. Additionally, economic impacts of COVID-19 like job losses may restrict healthcare budgets and access to expensive drugs and therapies for hyperparathyroidism. Overall, while the pandemic affected the market negatively in the short-run, increased acceptance of telehealth and prioritization of clearing surgical backlogs are expected to support market recovery in the coming years.

A majority of the global market value of hyperparathyroidism treatment is concentrated in North America, currently. This can be attributed to high per capita healthcare spending and advanced healthcare infrastructure in countries like the United States. Moreover, the presence of leading pharmaceutical companies developing novel drugs and widespread adoption of minimally invasive surgeries in the region contribute to its large market share. Within North America, the U.S. accounts for the lion's share due to the most developed pharmaceutical industry and favorable reimbursement scenario driving demand for therapies. Europe is the second largest regional market, while growth rates are higher in Asia owing to improving access and rising medical standards.

Asia Pacific region is poised to witness the fastest growth in the global Hyperparathyroidism Treatment Market over the next few years. Factors such as the rising geriatric population, growing per capita incomes, increasing focus on quality healthcare by both public and private players, and surging medical tourism are expected to drive higher growth rates in Asia compared to mature regions like North America and Europe. Within the Asia Pacific, China and India represent major markets with high prevalence and increasing access to healthcare. Government initiatives to enhance urban healthcare infrastructure and expand health insurance coverage are further facilitating market growth across Asia in this domain.